- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00844727
Coxib-inhibition of Duodenal Polyp Growth in FAP
July 3, 2011 updated by: Oslo University Hospital
Coxib-inhibition of Duodenal Polyp Growth in Familial Adenomatous Polyposis
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment.
The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Oslo, Norway, 0027
- Dept of Medicine, Rikshospitalet
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- FAP patient with previous colectomy and confirmed polyposis
Exclusion Criteria:
- Pregnancy
- Malignancy
- NSAID hypersensitivity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
placebo pills
|
Active Comparator: 1
Rofexocib 25 mg OD, 1 year treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2003
Primary Completion (Actual)
April 1, 2004
Study Completion (Actual)
April 1, 2004
Study Registration Dates
First Submitted
February 13, 2009
First Submitted That Met QC Criteria
February 13, 2009
First Posted (Estimate)
February 16, 2009
Study Record Updates
Last Update Posted (Estimate)
July 6, 2011
Last Update Submitted That Met QC Criteria
July 3, 2011
Last Verified
February 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Nasopharyngeal Neoplasms
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Rofecoxib
Other Study ID Numbers
- RH01/01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duodenal Polyposis
-
Copenhagen University Hospital, HvidovreCompletedDuodenal Cancer | Duodenal Polyposis | Familial Adenomatous PolyposesDenmark
-
Radboud University Medical CenterDutch Cancer SocietyCompletedFamilial Adenomatous Polyposis | Duodenal Neoplasms | Duodenal PolypsNetherlands
-
Johns Hopkins UniversityPentax MedicalActive, not recruitingFamilial Adenomatous Polyposis | Duodenal AdenomasUnited States
-
National Cancer Institute (NCI)RecruitingFamilial Adenomatous Polyposis | Colorectal Carcinoma | Attenuated Familial Adenomatous Polyposis | Duodenal CarcinomaUnited States, Puerto Rico
-
University Hospital, Strasbourg, FranceRecruitingCongenital Duodenal AtresiaFrance
-
M.D. Anderson Cancer CenterCompletedAttenuated Familial Adenomatous Polyposis | Deleterious Familial Adenomatous PolyposisUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedFamilial Adenomatous Polyposis (FAP)Italy
-
Assistance Publique - Hôpitaux de ParisAxcan PharmaUnknownAdenomatous Polyposis Coli, FamilialFrance
-
GlaxoSmithKlinePiramal Clinical Research (Hyderabad, India)Completed
-
Boston Children's HospitalRecruitingDuodenal AtresiaUnited States
Clinical Trials on Rofecoxib
-
Merck Sharp & Dohme LLCCompleted
-
Chinese University of Hong KongUnknown
-
Cancer Research Campaign Clinical Trials CentreCompletedColorectal CancerUnited Kingdom
-
Chinese University of Hong KongUnknown
-
Merck Sharp & Dohme LLCCompleted
-
Tremeau Pharmceuticals, Inc.TerminatedHemophilic ArthropathyUnited States, Italy, Turkey, Spain, Australia, Canada, Ukraine, Poland
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCTerminated